AllSci News
Pfizer's 25vPnC pneumococcal vaccine shows superior serotype 3 responses in Phase II pediatric study
Pfizer (NYSE: PFE) reported Phase II results for its 25-valent pneumococcal conjugate vaccine candidate PF-07872412 (25vPnC) in healthy infants, with...
BMS shakes with Anthropic to deploy Claude Enterprise across global pharma operations
Bristol Myers Squibb (BMS; NYSE: BMY, Princeton, NJ) and Anthropic announced a strategic agreement to deploy Claude AI as the company’s shared…
Bayer’s Hyrnuo gains FDA Priority Review for sBLA in first-line NSCLC
Bayer announced receipt of US FDA Priority Review for a supplemental New Drug Application (sNDA) for Hyrnuo (sevabertinib), an oral reversible HER2/EGFR…
IntraBio aiming Aqneursa as first ever treatment for ataxia-telangiectasia
IntraBio files for AQNEURSA approval in ataxia-telangiectasia, seeking first-ever treatment for the rare neurological disease
Gladstone Institutes receives USD 2m NIAID award for AI-guided phage therapy development
Gladstone Institutes has received a USD 2 million NIAID P01 award to establish the PhAIge Therapy Center, a multi-project preclinical program applying...
UCSD receives USD 2.5m NIDA grant for Brain-FRAMe HIV research program
University of California, San Diego has received a USD 2.5 million RM1 grant from the National Institute on Drug Abuse to launch Brain-FRAMe, a...
Roche and Medicines Patent Pool expand baloxavir marboxil access across 129 low- and middle-income countries
Roche (SIX: ROG) and the Medicines Patent Pool (MPP) announced the signing of a voluntary licence agreement covering baloxavir marboxil (Xofluza), Roche’s…
Monopar's Alxn1840 improves copper balance in Phase II Wilson disease trial
Monopar Therapeutics (Nasdaq: MNPR) has announced the publication of Phase II data showing that ALXN1840 (tiomolibdate choline) produced a statistically...
Tempus and Bristol Myers Squibb expand AI collaboration across oncology and neuroscience programs
Tempus AI (Nasdaq: TEM) and Bristol Myers Squibb (NYSE: BMY) announced an expansion of their existing partnership, applying Tempus’s Lens AI-enabled analytical…
LenioBio and Twist Bioscience partner to accelerate AI-driven protein and antibody discovery
LenioBio GmbH (Düsseldorf, Germany) and Twist Bioscience Corporation (Nasdaq: TWST) have formed an AI collaboration aimed at compressing the design–build–test cycle for…
Artiva's allogeneic NK cell therapy achieves 71% ACR50 response in refractory rheumatoid arthritis
Artiva Biotherapeutics (Nasdaq: ARTV) reported that its allogeneic NK cell therapy AB-101 (AlloNK), combined with rituximab, produced a 71% ACR50 response...
Incyte partners with Edison Scientific to deploy Kosmos agentic AI platform across drug discovery
Incyte (Nasdaq: INCY) has entered a collaboration agreement with Edison Scientific, a San Francisco-based AI company founded in 2025, to embed Edison's...
Sanofi's efdoralprin alfa outperforms plasma therapy in Phase II alpha-1 antitrypsin deficiency trial
Sanofi (Nasdaq: SNY) reported Phase II data showing efdoralprin alfa, a recombinant human AAT-Fc fusion protein, outperformed standard-of-care...
Accro Bioscience closes USD 50 million Series C to advance RIPK2 inhibitor ulcerative colitis
Accro Bioscience closes USD 50 million Series C to advance RIPK2 inhibitor in ulcerative colitis
Wave Life's RNA editing oligonucleotide restores wild-type M-AAT in early AATD trial
Wave Life Sciences (Nasdaq: WVE), based in Cambridge, Massachusetts, reported updated data from its Phase Ib/IIa WVE-006 RestorAATion-2 trial showing that...
The AllSci Brief
Free, systematic R&D and deal news. Daily.